**Background**
Nephrin was first identified in 1998. The Congenital Nephrotic Syndrome of the Finnish type is an autosomal recessive transmitted disease caused by a mutation in the NPHS1 gene that codifies nephrin. The clinical manifestations appear in the first three months of life and progress to end stage renal failure.

**Clinical case**
A seven weeks-old boy with normal grow and psycho-motor development was admitted to the emergency room with vomiting, diarrhoea and mild bilateral pretibial oedema. Laboratory data revealed anaemia, thrombocytosis, normal serum creatinine and urea, normal Na⁺, K⁺, pH and HCO₃⁻, hypoalbuminemia and proteinuria (263 mg/m²/day). The renal biopsy suggested a Congenital Nephrotic Syndrome of the Finnish type or mesangial sclerosis. The patient was treated with indomethacin and captopril for proteinuria without response. The genetic study confirmed the presence of the IVS9+4 (A>G) variant in homozygosity in the NPHS1 gene. His parents, first-degree cousins, had the same mutation in heterozygosity. The renal disease progressed to end stage renal failure at the age of four years-old. He was supported by continuous ambulatory peritoneal dialysis until the age of six, when he was successfully transplanted with a cadaveric kidney graft.

**Conclusions**
The role of nephrin in the glomerular filtration and stability of the podocytes is unequivocally established. The Congenital Nephrotic Syndrome of the Finnish type, initially found in Finnish families, is present in other areas of the world. The identification of a new mutation in the NPHS1 gene reflects the great variability in the mutations associated with the disease.

---

**PO-0787**

**CONGENITAL NEPHROTIC SYNDROME OF THE FINNISH TYPE – A NEW MUTATION ENTERS THE SCENE**

1) Lorenzo, 2) Beirão, 3) Matos, 3) Common Fear, Centro Hospitalar Entre Douro E Vouga, Porto, Portugal; 2) Nephrology, Centro Hospitalar Do Porto, Porto, Portugal; 3) Paediatric Nephrology, Centro Hospitalar Do Porto, Porto, Portugal

10.1136/archdischild-2014-307384.1423

**Introduction**
Continuous Veno Venous Haemofiltration (CVVH) is the extracorporeal renal support therapy of choice in PICU at OLCHC.¹ It is an extracorporeal blood treatment where ≤8% of patients blood is passed through a haemofilter. It removes fluid and waste products from the body in a gradual and controlled way avoiding massive fluid shifts.² CVVH in PICU OLCHC CVVH in OLCHC has seen a considerable expansion over the last 5 years. There are currently 21 CVVH specialists, including a CVVH co-ordinator in post. 2–3 specialists are on duty every shift which ensures continuous service availability. CVVH specialists require 60 pump hours/year to maintain competency. Wet labs are used to facilitate training. CVVH is provided using the Aquarius® which offers a paediatric mode, a safer therapy choice in children (Nikkiso, Co, Ltd).

**Results**
The CVVH service has progressively developed, as is evident in Figure 1. In 2011, 8 patients were supported with CVVH with a run time of 639 h, by 2013 this number increased to 15 patients and the run time had tripled.
Discussion The progressive increase in patients supported with this therapy mirrors its remarkable growth internationally. CVVH is the most dominant form of artificial renal support in Australian and European critical care, and its role as adjuvant therapy in sepsis is attracting increased focus. Conclusion CVVH activity is increasing at our institution, facilitated by a competent and flexible team of CVVH specialists. Future adequately powered multivariate logistic regression analysis should address outcomes of patients supported on CVVH.

Background Hypercalciuria has been considered as a predisposing factor for recurrent urinary tract infection (UTI) in recent studies. The mechanism may be related to uroepithelial injury by calcium microcrystals. The aim of this study was to evaluate the association of idiopathic Hypercalciuria with recurrent UTI in children.

Methods In this analytic study urine calcium:creatinine ratio of 40 children at the age of 2–16 years with recurrent urinary tract infection (without urinary tract anomalies and voiding dysfunction) was compared with 40 age and sex matched healthy children. Calcium:creatinine ratio more than 0.2 in a spot urine test was considered as hypercalciuria. Cases with hypercalcemia were excluded from the study. Recurrent UTI was defined as at least 3 episodes of UTI during 1 year or 2 episodes in 6 months.

Results Mean age of patients was 5 ± 2.22 years and mean age of control group was 5.13 ± 1.98 years. The mean calcium:creatinine ratio in case group (0.21 ± 0.17) was significantly higher than control group (0.08 ± 0.08) (p < 0.05). Hypercalciuria was detected in nineteen out of forty patients in case group (47.5%) and in 7.5% of control group (p < 0.001). History of familial urolithiasis was positive in 21% of hypercalciuric patients. There was no significant difference in frequency of urinary symptoms between hypercalciuric and normocalciuric patients with recurrent UTI.

Conclusion Children who suffer from recurrent UTI in spite of absence of urinary tract anomalies should be checked for hypercalciuria. Control of hypercalciuria with low salt regimen and high fluid intake and treatment with hydrochlorothiazide may decrease UTI episodes.

Background and aims Deferasirox is a novel oral iron chelator for the treatment of iron-overload due to chronic hypertransfusion. Renal toxicity due to deferasirox was more recognised and deferasirox-induced tubulopathy has been increasing reports in the literature. We report a b-Thalassemia paediatric patient who developed Fanconi Syndrome (FS), AKI and vitamin D deficiency after deferasirox therapy.

Methods Patient’s information was summarised and compared with literature.

Results A 4.8-year-old girl with b-Thalassemia major commenced hypertransfusion at 1.3-year-olds and received deferasirox 21 mg/kg/day at 1.9-year-olds, which baseline serum ferritin was 2,216 ng/ml. After increasing deferasirox to 35 mg/kg/day for 11 months, serum ferritin was lowering to 781 mg/ml. She was admitted with gastroenteritis, which revealed severe normal anion gap hyperchloremic hypokalaemic acidosis, severe hypophosphatemia, hypocalcemia, glucosuria, albuminuria, phosphaturia and vitamin D deficiency. Serum creatinine increased from 0.45 mg/dl to 0.75 mg/dl before turning to normal two months following cessation of deferasirox, as others except acidosis that persistently need alkali treatment. There were only five paediatric cases reported for deferasirox-induced FS in b-Thalassemia patients and 2 out of 5 that presented AKI. A prospective study in children reported 2 out of 10 cases presented deferasirox-induced FS, which 90% were Thalassemia patients. Recovery of FS and AKI also literally presented within 3 months after deferasirox’s cessation.

Conclusions - Deferasirox is potentially associated with renal toxicity in children, particularly FS and AKI.

- Diligent and regularly monitoring of renal function should be mandated in deferasirox receiving patients.

- Long-term consequences of kidney in deferasirox-treated children desire for further study.

Background Vasculitis presents several diagnostic challenges because patients could present with protean clinical manifestations and the range of differential diagnosis is broad. We report a pulmonary-renal syndrome in a 10-year-old boy referred to the Institute for Maternal and Child Healthcare.

Materials and methods A 10-year-old boy presented in April 2013 with rhinitis, fever and dry cough. His examination results were unremarkable except mild anaemia (9.9 g/dl) and markedly increased erythrocyte sedimentation rate (44 mm/h). A month later he had been admitted with complaints of proteinuria, hematuria and anaemia. In June he developed also arthrits. In October 2014 the child was admitted to the Paediatric Intensive Care Unit in a severe condition with rapidly progressive renal failure.

Results and discussion Antineutrophil cytoplasmic antibodies (ANCA) were positive with antigen specificity for myeloperoxidase (anti-MPO 37 KU/L). The other laboratory results included: mild anaemia and leukocytosis; proteinuria (69 mg/kg/day); increased blood urea nitrogen (BUN) and creatinine (10.4 mmol/L and 123 mmol/L, respectively). Thoracic CT revealed a solitary nodule 1.5 × 1 cm in the posterio-basal segment of the inferior lobe in the left lung. The next step would be to perform renal biopsy to confirm the diagnosis.

Conclusions Our aim in presenting this case is to alert clinicians that, even without the definitive histological diagnosis, it is